Indaptus Therapeutics is no longer best understood as an actively enrolling oncology developer: its clinical program has stopped, while its financing capacity and search for a different operating direction have expanded. EDGAR confirms the legal issuer as Indaptus Therapeutics, Inc., with CIK 1857044 and common stock trading as INDP on the Nasdaq Capital Market. The requested CAR-T classification does not describe its technology. Its historical lead asset, Decoy20, is a bacterial immunotherapy rather than an engineered T-cell treatment. More importantly, management disclosed that no participants remained in active studies and that no new clinical trial was currently planned. This report covers the June quarter and subsequent disclosed events through the report date, separating completed financings from signed transactions whose closing has not been verified. Annual identity and business description Quarterly operating update
The balance-sheet recovery is real, but it was purchased with a much larger share count rather than generated by the business. Quarter-end cash and redeemable deposits totaled approximately $11.6 million. First-half operating cash consumption remained approximately $8.9 million despite a much smaller accounting loss. The reason is that payments of old accrued obligations offset much of the benefit from lower current spending. Consequently, a smaller loss does not yet establish a stable new cash-burning rate. The investment proposition has shifted toward capital allocation, governance, and the economic terms of any replacement activity, with the legacy immunotherapy providing an uncertain asset-recovery opportunity rather than a scheduled clinical catalyst. Financial statements and strategic review
September added a signed private placement for approximately $24 million gross, alongside an expanded at-the-market program with a $100 million contractual ceiling. Neither figure is interchangeable with unrestricted cash already received. The private placement remained conditional in the reviewed announcement, and the market-sale facility requires actual buyers and remains subject to issuance eligibility. The analytical stance is cautious: funding can prolong the corporate search, but there is not yet enough operating evidence to assign a defensible earnings multiple or clinical success valuation. A credible change in that stance requires a defined development program or transaction, transparent spending commitments, and a share count that incorporates the financing used to obtain it. Private placement terms Amended market-sale arrangement